CureVac B.V.

$CVAC shares jumped today as rival German biotech firm BioNTech has agreed to acquire CureVac for about $1.25 billion worth of BioNTech shares.

Share this article:

About the Author:

CureVac B.V.

Joey Ramson

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup